DUBLIN, June 15, 2020 /PRNewswire/ --
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced along with its partner PharmaMar (MSE: PHM) that the U.S. Food and Drug Administration (FDA) approved Zepzelca™ (lurbinectedin) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.1 Zepzelca was approved under accelerated approval based on overall response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.1
The FDA approval of Zepzelca is based on monotherapy clinical data from an open-label, multi-center, single-arm study in 105 adult platinum-sensitive and platinum-resistant patients with SCLC who had disease progression after treatment with platinum-based chemotherapy.2 The data, which appeared in The Lancet Oncology May 2020 issue, showed that in patients with relapsed SCLC, Zepzelca demonstrated an ORR of 35 percent and a median duration of response of 5.3 months as measured by investigator assessment (30 percent and 5.1 months respectively, as measured by an independent review committee (IRC)).1
"Small cell lung cancer is a disease with limited treatment options, and the approval of Zepzelca represents an important advance for patients whose metastatic SCLC has progressed on or after platinum-based therapy," said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals. "While patients may initially respond to traditional chemotherapy, they often experience an aggressive recurrence that is historically resistant to treatment. Jazz congratulates PharmaMar on the successful development of Zepzelca and we are proud to partner with them to bring this new therapy to the U.S. market, expanding our presence in oncology."
Zepzelca will be commercially available in the U.S. in early July. As previously announced in December 2019, PharmaMar and Jazz entered into an exclusive license agreement, which became effective in January 2020, granting Jazz U.S. commercialization rights to Zepzelca.
"Seeing first-hand the aggressive nature of SCLC and knowing that the large majority of those diagnosed will experience relapse, I am excited to see an effective new treatment demonstrating durable responses," said Dr. Jeff Petty, oncology specialist, Wake Forest Baptist Health. "For doctors, patients and their families, Zepzelca is an important and much-needed addition to the treatment landscape for relapsing SCLC."
"We are pleased to bring a new treatment choice to relapsed SCLC patients," said José María Fernández Sousa-Faro, PhD, president of PharmaMar. "The U.S. FDA accelerated approval of Zepzelca underscores its potential to fill an unmet need in this often-overlooked SCLC community." ...
Actualmente se está Procediendo al Diseño del Siguiente Ensayo Clínico para Progresar con el Desarrollo Clínico del Producto Especialmente Dirigido a los Pacientes que Muestran más Severidad en la Enfermedad, como aquellos con Síndrome de Sjögren, ya que Estos en el Estudio Helix Mostraron una Especial Mejoría de Signos y Síntomas.
Adicionalmente la Compañía está Trabajando en Nuevos Candidatos basados en la tecnología del RNAi para el Tratamiento de las Alergias
Oculares y de Enfermedades de Retina. Estos nuevos Candidatos se ha Analizado la Eficacia en Modelos Preclínicos para dichas Patologías .
El " YA Candidato SYL1801 " para el Tratamiento Tópico de la Enfermedad de Degeneración Macular asociada la Edad ha Completado los Estudios Preclínicos de Toxicología Regulatoria en dos especies animales, los resultados indican que el producto presenta un buen perfil de seguridad y no se han encontrado efectos toxicológicos del SYL1801 tras la administración continuada del producto por vía ocular. Durante este año se ha completado el diseño del ensayo de fase I para el SYL1801 que se llevará a cabo durante el año 2020 .
